Ken Griffin G1 Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$2.2 - $4.98 $417,120 - $944,208	189,600 Added 212.79%	278,700 $635,000
Q1 2024 May 15, 2024	BUY	$2.1 - $4.83 $81,900 - $188,370	39,000 Added 77.84%	89,100 $384,000
Q4 2023 Feb 14, 2024	SELL	$1.12 - $3.73 $17,808 - $59,307	-15,900 Reduced 24.09%	50,100 $152,000
Q3 2023 Nov 14, 2023	BUY	$1.22 - $2.67 $48,434 - $105,999	39,700 Added 150.95%	66,000 $95,000
Q2 2023 Aug 14, 2023	SELL	$2.46 - $3.14 $78,720 - $100,480	-32,000 Reduced 54.89%	26,300 $65,000
Q1 2023 May 15, 2023	BUY	$2.57 - $8.16 $26,985 - $85,680	10,500 Added 21.97%	58,300 $156,000
Q4 2022 Feb 14, 2023	BUY	$5.19 - $13.5 $117,294 - $305,100	22,600 Added 89.68%	47,800 $259,000
Q3 2022 Nov 14, 2022	BUY	$5.17 - $16.99 $130,284 - $428,147	25,200 New	25,200 $315,000

3.55M

11.7K

Ticker GTHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,746,800
Market Cap $306M
Description
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.